Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Trial Profile

Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Anastrozole (Primary) ; Everolimus (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms Treat ER+ight
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Dec 2019 to 2 Dec 2019.
    • 06 Feb 2018 Planned primary completion date changed from 1 Dec 2019 to 2 Dec 2019.
    • 11 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top